Showing results (1-10 of 453) with videos related to
Sort By:
Pageof 46
Cancer Discovery|July 8, 2017
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the DarknessJordi Rodon, Josep TaberneroAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2021
Taking Aim at the UndruggableNiamh Coleman, Jordi RodonCurrent Opinion in Oncology|March 16, 2013
Biomarker-driven patient selection for early clinical trialsRodrigo Dienstmann, Jordi Rodon, Josep TaberneroThe Oncologist|October 19, 2013
Pilot studies for personalized cancer medicine: focusing on the patient for treatment selectionLeticia De Mattos-Arruda, Jordi RodonHandbook of Clinical Neurology|March 8, 2016
Principles of pharmacotherapyTracy Batchelor, Jordi Rodon, Manmeet AhluwaliaSeminars in Oncology|November 29, 2015
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid TumorsCinta Hierro, Jordi Rodon, Josep TaberneroThe Oncologist|January 19, 2010
Combining targeted therapies: practical issues to consider at the bench and bedsideJordi Rodon, Jose Perez, Razelle KurzrockNPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep TaberneroMolecular Oncology|August 2, 2014
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the testRodrigo Dienstmann, Jordi Rodon, Josep TaberneroPageof 46